MRNA Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2,385.00 |
| 52 Week High | US$11,150.00 |
| 52 Week Low | US$2,135.00 |
| Beta | 1.69 |
| 11 Month Change | -29.33% |
| 3 Month Change | -58.59% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRNA | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | 4.8% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MRNA performed against the AR Biotechs industry.
Return vs Market: Insufficient data to determine how MRNA performed against the AR Market.
Price Volatility
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: MRNA's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of AR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| MRNA fundamental statistics | |
|---|---|
| Market cap | AR$15.89t |
| Earnings (TTM) | -AR$2.23t |
| Revenue (TTM) | AR$5.10t |
3.1x
P/S Ratio-7.1x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNA income statement (TTM) | |
|---|---|
| Revenue | US$5.08b |
| Cost of Revenue | US$6.48b |
| Gross Profit | -US$1.40b |
| Other Expenses | US$824.00m |
| Earnings | -US$2.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.78 |
| Gross Margin | -27.55% |
| Net Profit Margin | -43.77% |
| Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison